Related Experiment Video
Updated: Aug 9, 2026
Murine Heterotopic Heart Transplant Technique
Published on: July 8, 2014
Percutaneous revascularization modalities in heart transplant recipients
O Topaz1, M J Cowley, P K Mohanty
1Cardiac Catheterization Laboratories, McGuire VA Medical Center and Medical College of Virginia Hospitals, Medical College of Virginia, Virginia Commonwealth University, Richmond 23249, USA.
Insights
Accelerated allograft vasculopathy, a major cause of heart transplant failure, presents challenges for interventional treatments. New revascularization devices show promise but require further long-term outcome evaluation.
Area of Science:
- Cardiology
- Transplantation immunology
- Interventional cardiology
Background:
- Accelerated allograft vasculopathy (AAV) significantly limits long-term survival in heart transplant recipients.
- Allograft coronary artery disease (ACAD) affects up to 50% of recipients within 5 years, leading to heart failure or sudden cardiac death.
Observation:
- Percutaneous balloon angioplasty is a palliative option for focal ACAD but has high restenosis rates.
- Debulking devices and emerging modalities like coronary stents, rotational atherectomy, and lasers are being explored for both focal and diffuse ACAD.
Findings:
- While stents may reduce restenosis in focal lesions, their efficacy in diffuse ACAD remains unknown.
- Current interventional approaches face limitations due to restenosis and disease progression in untreated segments.
Implications:
- Further research is needed to assess the long-term outcomes of novel revascularization devices for ACAD.
- Accurate clinical outcome assessment is crucial before adopting new interventional tools for ACAD treatment.
Abstract:
Accelerated allograft vasculopathy significantly limits the survival of heart transplant recipients. The prevalence of allograft coronary artery disease is as high as 18% by 1 year and 50% by 5 years following heart transplant. Heart failure and sudden cardiac death are the two most common clinical presentations. In heart transplant recipients with severe, discrete focal allograft vascular disease, percutaneous balloon angioplasty is a viable palliative option. However, its application is limited by a significant restenosis rate and progression of allograft disease in nontreated segments. Diffuse disease with tapering of vessels may be approached by debulking devices. Emerging revascularization modalities for focal stenoses and some of the diffuse tapering vessels include coronary stents, rotational atherectomy, various wavelength lasers, and, to a lesser extent, directional atherectomy. Conceivably, stents will reduce restenosis rates related to focal, discrete plaques; yet it is unknown whether they will be efficacious in short- and long-term treatment of diffusely diseased segments affected by allograft disease. Accurate assessment of clinical outcomes and long-term evaluation is imperative prior to acceptance of these devices as fundamental interventional tools for treatment of allograft coronary artery disease.
